OSE Immunotherapeutics Adds Boehringer Ingelheim To Its Pharma Partnering List

09 Apr 2018

• By Sten Stovall

Collaborating with the German family-controlled drug maker on OSE's novel checkpoint inhibitor aligns with French firm's strategy of partnering its portfolio candidates.

Laboratory — OSE and BI To Start OSE-172 Phase I Trials In Early 2019 • Source: Shutterstock

Impressive preclinical studies have prompted Boehringer Ingelheim GMBHto license OSE Immunotherapeutics SA' s novel checkpoint inhibitor antibody that's designed to treat advanced solid tumors, in a deal that could generate up €1.1bn for the French biotech.

The pact, announced April 4, gives the Germany-based group global rights to develop, register and commercialize OSE-172, which has obtained proof of concept in models of aggressive cancers such as breast cancer, melanoma and primary liver cancer, and is now likely to enter Phase I testing

First Blood-Based Test Cleared For Alzheimer’s Boosts Anti-Amyloid Drugs

19 May 2025

• By Mandy Jackson

The US FDA approval of Fujirebio’s Lumipulse should boost access to medicines like Eisai’s Leqembi and Lilly’s Kisunla; the firms are praising patients’ access to earlier diagnoses.